Revenue Update on Aptose Biosciences Inc(NASDAQ:APTO)

Aptose Biosciences Inc(NASDAQ:APTO) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 28, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.26.

Aptose Biosciences Inc (APTO) made into the market gainers list on Fridays trading session with the shares advancing 0.88% or 0.01 points. Due to strong positive momentum, the stock ended at $1.14, which is also near the day’s high of $1.14. The stock began the session at $1.13 and the volume stood at 69,761 shares. The 52-week high of the shares is $4.2999 and the 52 week low is $0.834. The company has a current market capitalization of $15 M and it has 1,34,55,384 shares in outstanding.

Aptose Biosciences Inc. (Aptose) is a clinical stage biotechnology company. The Company is engaged in development of targeted therapies addressing unmet medical needs in oncology. The Company has product candidates in two classes of anti-cancer therapies: Small molecule program and large molecule program. The Company’s group of small molecule compounds includes lead drug APTO-253 in acute myeloid leukemia (AML) myelodysplastic syndromes (MDS) and other hematologic malignancies. APTO-253 is an inducer of the Kruppel-like factor 4 gene (the Klf4 Gene) for patients with advanced hematologic malignancies. Additionally the Company has a preclinical small molecule program APTO-500 targeting maternal embryonic leucine zipper kinase (MELK) for the treatment of various cancers. The Company’s large molecule program includes a molecule to target specific cell-surface receptors expressed in certain cancers expressing the Interleukin-17E receptor (IL-17ER).

Add Comment